Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A

Thrombosis and Haemostasis

Volumn 90, Issue 5, 2003, Pages 813-822

  Misra, Namita ^a   Bayry, Jagadeesh ^a   Pashov, Anastas ^a   Kaveri, Srini V ^a   D'Oiron, Roseline ^b   Stieltjes, Natalie ^c   Roussel Robert, Valeri ^c   Kazatchkine, Michel D ^a   Boyer, Olivier ^d   Lacroix Desmazes, Sébastien ^a  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

^c Hôpital Cochin ^*  (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

FVIII inhibitor; Hemophilia A; Repertoire development; T cell receptors; T lymphocytes

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; CD4 ANTIGEN; INTERFERON; PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; V BETA PROTEIN;

ADULT; AGED; ARTICLE; BETA CHAIN; BLOOD DONOR; CELL HETEROGENEITY; CELL ISOLATION; CELL SPECIFICITY; CELL STIMULATION; CLINICAL ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOREGULATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN LOCALIZATION; T LYMPHOCYTE; TARGET CELL; TREATMENT PLANNING; VIRUS INFECTION;

EID: 10744226043     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-05-0300     Document Type: Article

References (37)

1. Peake I. The molecular basis of haemophilia A. Haemophilia 1998; 4: 346.
2. de Biasi R, Rocino A, Papa ML, et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
3. Schwaab R, Brackmann HH, Meyer, C, et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
4. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. Catalytic activity of antifactor VIII antibodies (FVIII inhibitors) in patients with hemophilia A. Nature Med 1999; 5: 1044-7.
5. Lacroix-Desmazes S, Bayry J, Misra N, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346: 662-7.
6. Singer ST, Addiego JE Jr., Reason DC, et al. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
7. Reding MT, Wu H, Krampf M, et al. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
8. Jacquemin M, Vantomme V, Buhot C, et al. CD4+ T-cell clones specific for wild-type factor VIII: A molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
9. Qian J, Borovok M, Bi L, et al. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-4.
10. Sasgary M, Ahmad RU, Schwarz HP, et al. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
11. Wu H, Reding M, Qian, J, et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
12. Reding MT, Wu H, Krampf M, et al. Sensitization of CD4+ T cells to coagulation factor VIII: Response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
13. Ria F, van den Elzen P, Madakamutil LT, et al. Molecular characterization of the T cell repertoire using immunoscope analysis and its possible implementation in clinical practice. Curr Mol Med 2001; 1: 297-304.
14. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: Improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
15. Benveniste O, Cherin P, Maisonobe T, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001; 167: 3521-9.
16. Roglic M, Macphee RD, Duncan SR, et al. Theofilopoulos A N. T cell receptor (TCR) BV gene repertoires and clonal expansions of CD4 cells in patients with HIV infections. Clin Exp Immunol 1997; 107: 21-30.
17. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998; 4: 215-21.
18. Beurton I, Bertrand MA, Bresson-Hadni S, et al. Interferon alpha therapy in haemophilic patients with chronic hepatitis C: A French multicentre pilot study of 58 patients. Eur J Gastroenterol Hepatol 2001; 13: 859-64.
19. English KE, Brien WF, Howson-Jan K, et al. Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy. Ann Pharmacother 2000; 34: 737-9.
20. Reding MT, Lei S, Lei H, et al. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 568-75.
21. Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
22. Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100: 855-66.
23. Yoshizawa K, Ota M, Katsuyama Y, et al. T cell repertoire in the liver of patients with autoimmune hepatitis. Hum Immunol 1999; 60: 806-15.
24. Grabowska AM, Lechner F, Klenerman P, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001; 31: 2388-94.
25. Umemura T, Yoshizawa K, Ota M, et al. Analysis of T cell repertoire in the liver of patients with chronic hepatitis C. Clin Exp Immunol 2000; 121: 120-6.
26. Turner SJ, Diaz G, Cross R, et al. Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity 2003; 18: 549-59.
27. Ouyang Q, Wagner WM, Walter S, et al. An age-related increase in the number of CD8(+) T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev 2003; 124: 477-85.
28. Cibotti R, Cabaniols JP, Pannetier C, et al. Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J Exp Med 1994; 180: 861-72.
29. Prisco A, Troncone R, Mazzarella G, et al. Identical T-cell receptor beta chain rearrangements are present in T cells infiltrating the jejunal mucosa of untreated celiac patients. Hum Immunol 1997; 55: 22-33.
30. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: Management. Semin Thromb Haemost 2000; 26: 179-88.
31. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
32. Ewenstein BM, Hoots WK, Lusher JM, et al. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85: 35-9.
33. Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential. J Neurosci Res 1996; 43: 391-402.
34. Aissaoui A, Klingel-Schmitt I, Couderc J, et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol 1999; 46: 559-67.
35. Qian J, Burkly LC, Smith EP, et al. Role of CD154 in the secondary immune response: The reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
36. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
37. Patterson AE, Korngold R. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 187-96.